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Recent scientific advances centred on the use of anti-
retrovirals (ARVs)  both prophylactically to prevent HIV
acquisition (pre-exposure prophylaxis, or PrEP) and for treat-
ment to minimize onward transmission (treatment as preven-
tion, or TasP)  have led to a new-found optimism for control
of the HIV/AIDS epidemic and the possibility of creating an
‘‘AIDS-free generation’’ [1]. In order to translate this optimism
into reality, large and sustained reductions in incident HIV
infections are required. Several models have projected that
with substantial programmatic scale-up of the new prevention
agenda, such requirements can be satisfied [2]. However,
these models typically assume a uniform efficiency for inter-
ventions in reducing incident infections across populations,
and neglect to consider their current unavailability to a key
population driving the epidemic at its epicentre: adolescent
girls.
In sub-Saharan Africa, which continues to bear a dispropor-
tionate burden of new HIV infections, almost a third of new
infections occur in young women aged between 15 and 24
years [3]. In this region, a defining characteristic of the epi-
demic is the age-sex distribution in HIV acquisition, wherein
women acquire HIV infection about five to seven years earlier
than their male peers, often synonymously with sexual debut
[4]. Particularly in southern Africa, this age-sex difference
in HIV acquisition rates has contributed to unprecedentedly
high incidence rates in adolescent girls, and continues to
sustain the epidemic. In South Africa, more than 20% of young
pregnant women aged 1524 years attending antenatal clinics
are HIV positive, and more than three-quarters of HIV-positive
young people aged 1524 years are women [5]. The reasons
for such high rates of new infections are complex and are
compounded by a number of structural, social and biological
factors; however, what is clear is that an AIDS-free generation
cannot be realized unless new infections in adolescent girls
are eliminated. This is a public health imperative.
The HIV prevention interventions available to this popula-
tion are abstinence, promotion of condom use, behaviour
change (including delay of sexual debut) and conditional cash
transfers to encourage high school completion. However,
these interventions are highly variable in their robustness
and, given the underlying gender-power dynamics in the
sub-Saharan African setting, they are likely to be of limited
immediate benefit for the most vulnerable young women.
Moreover, while community-based interventions and school-
based education programmes to address the underlying eco-
nomic and social vulnerability of adolescent girls should be
encouraged, this is a substantial task that will potentially
require decades of concentrated action, during which time
adolescent girls will continue to become infected.
Furthermore, immediate measures to protect adolescent
girls are urgently needed. However, new prevention advances
that may have the potential to afford such immediate pro-
tection are currently unavailable to adolescent girls despite
potentially substantial population- and individual-level bene-
fit because of exclusion of young women under 18 years of
age from trial participation. There is thus an urgent need to
validate the safety and efficacy of existing technologies for use
in adolescents, which may take several years to accomplish.
In the interim, the need for safe and efficacious prevention
options is immense and growing. As this gap is filled, it is
critical not to increase the deficit, and future prevention trials,
including vaccine trials, should include adolescent girls from
the outset.
As important as the inclusion of adolescent girls in pre-
vention trials is the inclusion of adolescent girls in treat-
ment trials to address the needs of the significant proportion
of adolescents who are already living with HIV. Indeed, in
Lesotho, an estimated 20% of all young people aged 1524
years are infected with HIV, and adolescents (1019 years) are
the only age group in which AIDS deaths have risen between
2001 and 2012 [6].
The epidemiological evidence for the high risk and burden
of HIV in adolescent girls is overwhelming and, together with
the lack of evidence of protection from behavioural interven-
tions, has prompted this and other calls for their inclusion
in both biomedical prevention and treatment trials. The recent
establishment of the Lancet Adolescent Commission is in
recognition of the global importance of this key population
[7]; yet in the absence of evidence-based HIV prevention
approaches, it may have limited impact. To facilitate adoles-
cent participation in clinical and preventive trials, by extension
we are also calling for increased research on key parameters in
adolescents and for a more enabling ethico-legal framework
conducive to adolescent recruitment. Currently, moral and
judgemental values override the epidemiological evidence in
decisions relating to the autonomous inclusion of adolescents
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in research, notwithstanding consensus documents generated
by UNAIDS on the importance of the inclusion of adolescents
in HIV preventive vaccine trials [8]; the dearth of data on
adolescents is lagging behind the policy and practice dis-
course. Consolidation of available data from treatment provi-
sion and sexual reproductive health service provision services
targeted at African adolescents will be an important first step
in enhancing our understanding of pathogenesis and disease
progression in this population to inform prevention and
treatment efforts.
A major barrier to the inclusion of adolescents in research
is restrictive ethico-legal frameworks [9]. Ethics guidelines
and legislation are based on historical protection of minors
who are perceived to be incapable of providing autonomous
consent. In communities where, prior to ARV treatment
access, large numbers of adults were decimated by AIDS,
there are now large numbers of child-headed households.
Here, adolescents take responsibility for themselves and their
younger siblings, and show considerable maturity; yet they
are unable to independently take steps to participate in HIV
research due to lack of parental consent. Further barriers to
obtaining parental consent in the realities of sub-Saharan
African settings result from high levels of migration for em-
ployment, which perturb traditional family structures, and the
typical tendency of not formally establishing legal guardian-
ship in the absence of parents.
Beyond barriers to participation, stipulating the need for
parental consent in current guidelines may inadvertently be
placing an already vulnerable population at risk of harm.
Indeed, non-autonomous participation of adolescents may
necessitate breaching the confidentiality of research partici-
pants, particularly with regard to parental disclosure of sexual
activity and/or HIV status. Such breaches of confidentiality
could place participants at potential risk of harm given that
discrimination, violence and social ostracism are commonly
experienced by those whose HIV status is disclosed to family
or community members in this setting. Even for HIV-negative
participants, there may be a risk of discrimination as involve-
ment in preventive trials carries implications for their levels
of sexual activity.
The need to include adolescents in HIV research must be
carefully balanced against the need to protect them and,
clearly, if autonomous participation for adolescents is widely
adopted, it should be carefully regulated to protect adoles-
cents from any harm associated with research, particularly
relating to potential reactions to discovery of HIV-positive
status. Indeed, adolescents seeking autonomous participa-
tion should be able to demonstrate appropriate cognitive and
emotional maturity during informed consent procedures
and throughout the trial, for example, by successful comple-
tion of a cognitive and emotional maturity assessment. Other
methods of minimizing harm could include the establishment
of committees of community members capable of overseeing
consent procedures. These are complex challenges with no
easy answers, but they must be proactively and pragmatically
addressed as we consider the cost and harm of inaction.
To conclude, the unprecedentedly high HIV incidence rates
in adolescent girls make their inclusion in HIV research a pub-
lic health imperative, both in terms of their own protection or
treatment access, and for realizing the goal of an ‘‘AIDS-free
generation.’’ To this end, a concerted effort is required by all
stakeholders as a matter of urgency to ensure a safe and
enabling framework for participation of adolescents in HIV
research to ultimately facilitate access to much-needed
evidence-based HIV prevention and treatment services. Young
women have a right to remain HIV uninfected, and allowing
this right to be exercised has both individual and population
benefits. In the context of the HIV epidemic, autonomous
decision making by adolescents could enable this process and,
in future, offer some protection to vulnerable women that
science cannot yet afford them.
Authors’ affiliations
CAPRISA, Nelson R Mandela School of Medicine, University of KwaZulu-Natal,
Durban, South Africa
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
QAK and RD jointly conceptualized and prepared this manuscript.
Acknowledgements
RD is a research fellow supported by the CAPRISA Training Programme.
References
1. Fauci AS, Folkers GK, Dieffenbach CW. HIV-AIDS: much accomplished, much
to do. Nat Immunol. 2013;14(11):11047.
2. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary
HIV testing with immediate antiretroviral therapy as a strategy for elimination
of HIV transmission: a mathematical model. Lancet. 2009;373(9657):4857.
3. Joint United Programme on HIV/AIDS (UNAIDS). World AIDS Day Report.
2011 [cited 2014 Feb 6]. Available from: http://www.unaids.org/en/media/
unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_
report_2011_en.pdf
4. Abdool Karim Q, Kharsany AB, Frohlich JA,Werner L, Mashego M, Mlotshwa
M, et al. Stabilizing HIV prevalence masks high HIV incidence rates amongst
rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol.
2011;40(4):92230.
5. Department of Health. The 2011 National Antenatal Sentinel HIV and
Syphilis Prevalence Survey. Pretoria: Epidemiology and Surveillance, National
Department of Health; 2011 [cited 2014 Feb 6]. Available from: http://
www.health.gov.za/docs/reports/2013/Antenatal_survey_report_2012_web_
optimized.pdf
6. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2013 UNAIDS
Report on the global AIDS epidemic. Geneva: UNAIDS; 2013 [cited 2014
Feb 6]. Available from: http://www.unaids.org/en/media/unaids/contentassets/
documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf
7. Patton GC, Ross DA, Santelli JS, Sawyer SM, Viner RM, Kleinert S. Next steps
for adolescent health: a Lancet Commission. Lancet. 2014;383(9915):3856.
8. Joint United Nations Programme of HIV/AIDS (UNAIDS). Ethical considera-
tions in HIV preventive vaccine research. Geneva: UNAIDS; 2000 [cited 2014
Feb 6]. Available from: http://data.unaids.org/Publications/IRC-pub01/JC072-
EthicalCons_en.pdf
9. Singh JA, Abdool Karim SS, Abdool Karim Q, Mlisana K,Williamson C, Gray C,
et al. Enrolling adolescents in research on HIV and other sensitive issues:
lessons from South Africa. PLoS Med. 2006;3(7):180.
Abdool Karim Q and Dellar R. Journal of the International AIDS Society 2014, 17:19075
http://www.jiasociety.org/index.php/jias/article/view/19075 | http://dx.doi.org/10.7448/IAS.17.1.19075
2
